Nasus Pharma Ltd.

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company based in Tel Aviv, Israel, focused on developing powder-based intranasal products to address acute medical conditions and public health threats. The company's mission is to provide enhanced protection to patients during severe, life-threatening situations through effective, user-friendly, safe, and rapidly acting intranasal therapies.

Leveraging its proprietary Powder-Based Intranasal (PBI) or Nasax® technology, Nasus Pharma's pipeline includes NS002, an intranasal epinephrine product candidate for anaphylaxis, which is its lead program. The company also developed NS001, an intranasal naloxone powder nasal spray for opioid overdose, though work on this product has been paused and it is available for partnering. Additionally, Nasus Pharma is advancing early-stage programs such as NS003 for nausea and vomiting, NS004 for metabolic disorders, and NS005 for cardiovascular diseases.

Recent developments include positive Phase 2 data for NS002, demonstrating significantly faster and superior epinephrine delivery compared to EpiPen®, with a pivotal study planned for Q4 2026. In February 2026, the company completed a $15.0 million private placement to support the advancement of NS002 and its pipeline. Nasus Pharma became publicly traded in August 2025 following an IPO that raised $10 million. The leadership team includes CEO Dan Teleman, Co-founder and Chief Development Officer Dr. Dalia Megiddo, and Executive Vice President and CFO Eyal Rubin.